Industry Material
NEWS
Korean iPSC derived cell provider, Nexel, conducts another research Nexel and Chonnam National University have signed an MOU for research cooperation in the bio field
Dec 17, 2020, 06:42
Chonnam National University Hospital (Chief : Lee Sam-yong) announced that it has signed a business agreement with Nexel (CEO : Han Choong-seong) for research cooperation in the bio field.
The ceremony was attended by 20 people from both institutions, including hospital chief, president of the Institute of Biomedical Research, professor of circulatory internal medicine, and CEO of Nexel.
According to the agreement, the two organizations will ▲cooperate with each other on joint research results using induced pluripotent stem cells ▲consult on the use of the results derived from cooperation between the two institutions ▲share human derivatives and related information, and discuss research using them ▲promote mutual cooperation, etc.
Nexel is the only one in Korea that has the right to use an induced pluripotent stem cell patent from Kyoto University in Japan, and has succeeded in developing various somatic cell products targeting the global cell market for toxicity testing based on specialized stem cell differentiation technology.
Nexel is a Korean iPSC derived cell provider focusing on the development of new drugs and stem cell research and development, such as developing stem cell-derived somatic cell products for toxicity tests for the development of new drugs for liver cirrhosis, myocardial infarction, and lung fibrosis.
Chief Lee Sam-yong said, “Through this agreement, it was an opportunity to accelerate the development of new drugs for genetic diseases and stem cell development. We will provide full support so that we can achieve excellent research results leading the future medical care through cooperation between the two organizations.”
Meanwhile, Nexel is the first provider in Korea to acquire an induced pluripotent stem cell commercialization license, and launch cell products for toxicity evaluation of new drugs. Nexel is the only one in Korea to join the International Health and Environment Science Committee(HESI) research group and the International Drug Regulation and Harmonization Committee(ICH). Nexel is participating in the revising of the 'New Cardiac Toxicity Assessment Guideline'.
In addition, Nexel has successfully produced a model that can evaluate the efficacy of a candidate substance for treating Wilson's disease using human pluripotent stem cells, and the results of its research were published in the international journal 'Cells'.
For more information on Nexel, visit http://www.nexel.co.kr.
[Company Information]
Contact : Tel. +82-2-2088-8886 / support@nexel.co.kr
Related Link : http://www.nexel.co.kr
Written by Hanmir PRNews
► This is a news release distributed by Hanmir PR news on behalf of Nexel.
► News provided by Nexel
#nexel #cardiomyocytes derived from induced pluripotent stem cells #cell products #cardiac toxicity assessment methods #korean ipsc derived cell provider
HANMIR Writer
The HANMIR Online PR News is a go-to source that
focuses on small-medium sized enterprises in South Korea.
Media Contacts +82-(0)2-6265-2100 overseas@hanmir.co.kr